Vulvovaginal Disorders

Postmenopausal women with vulvovaginal atrophy treated with intravaginal prasterone for at least 12 weeks were nearly 50% less likely to develop a urinary tract infection compared with untreated women, researchers reported in Menopause.

Postmenopausal women assigned daily oral lasofoxifene had significant and clinically meaningful improvements in vulvovaginal atrophy symptoms with a favorable safety profile, researchers reported in Menopause.

Menopausal women experience multiple vulvovaginal symptoms with variations in quantity, severity and frequency, which cause significant interference in daily life, according to a post hoc analysis published in Menopause.

Treatment with a vaginal tamoxifen capsule in postmenopausal women with moderate to severe vulvovaginal atrophy was safe with minimal drug exposure, researchers reported in a phase 1/2 clinical study.